Introduction
Monoclonal antibodies that bind and inhibit nerve growth factor (NGF) have demonstrated both, good analgesic efficacy and improvement in function in patients with osteoarthritis (OA) and low back pain 1e5 . Despite initial promising data, trials in OA had been suspended in 2010 by the Federal Food and Drug Administration (FDA) due to concerns over accelerated rates of OA progression (i.e., rapid progressive osteoarthritis e RPOA) to total joint replacement particularly in the large joints of the lower limb 6, 7 . The observations about adverse events in tanezumab studies, one of the a-NGF compounds under investigation, lead to a report on the process and results of the adjudication of these events 8 These adverse events were observed in patients using NGF-inhibitors alone, and more commonly in combination with non-steroidal anti-inflammatory drugs (NSAIDs) suggesting that the cumulative analgesic effect of two separate classes of drugs prompted patients to permit increased joint loading lacking the usual pain that would limit such pathologic stress on an already damaged joint 5, 8 . The authors further reported a significant doseeresponse relationship between incident RPOA and increasing doses of tanezumab, which was greater when tanezumab was given in combination with NSAIDs 8 .
Since anti(a)-NGF therapies offer potential as the first new class of analgesics for many years, future studies of a-NGF compounds will require rigorous safety criteria. Imaging will play a crucial role in future clinical trials to define eligibility of potential participants and to monitor safety during the course of these studies. This will require baseline and frequent follow-up radiographs of both, the index joints and other large weight bearing joints to identify subjects at risk for RPOA and identify subjects on study with adverse events such as RPOA Type I or II so treatment can be discontinued. Additional magnetic resonance imaging (MRI) examinations will be important during the course of a study in cases of unexpected joint pain or swelling or in cases of discrepancy between clinical symptoms, mainly pain and radiographic findings 6 .
Thus, the aim of this imaging overview in the form of an atlas is to describe and illustrate potential exclusionary joint imaging findings at eligibility and potential adverse joint events on radiography and MRI in studies investigating a-NGF compounds. The overarching goal of this atlas is to facilitate trial design and to promote a common language and understanding between potential expert readers. This first section of the atlas will focus on knee joint specific findings that are relevant to a-NGF studies.
Methods
This atlas is based on eight in-person and 20þ teleconference meetings of four experienced musculoskeletal radiologists (FWR, CH, KH, AG) and a senior imaging expert (CGM) representing a contract research organization (CRO) active in a-NGF studies to define potential eligibility and safety findings relevant for a-NGF clinical trials. 400þ baseline and follow-up radiographic and MRI image examples of knee joints were reviewed in consensus to define the most relevant and characteristic imaging findings of entities that may be encountered during a-NGF studies at screening or during the course of a study. Images for this atlas were derived from personal teaching and training files of these radiologists and partly from a Pfizer library of knee radiographs obtained during the course of the tanezumab program. As the terminology for several of the potentially encountered findings is not uniform, the following section will briefly define those pathologic conditions for the purpose of this atlas.
The term osteonecrosis in the context of this atlas is used for a focal circumscribed or extended region of infarcted bone. "Avascular necrosis" and "bone infarct" are commonly used in synonymous fashion. Any focus of infarcted bone regardless of its location within the bone will be defined as osteonecrosis. The term "spontaneous osteonecrosis of the knee" (also called SONK or SPONK) will be summarized under subchondral insufficiency fracture (SIF), reflecting current etio-pathologic understanding 9, 10 .
RPOA Type 1 is defined as rapid loss of joint space width (which is defined as 2 mm or other protocol-specific cut-off) within approximately 1 year without evidence of bone loss or destruction. The diagnosis can only be established whenever prior images are available to allow longitudinal assessment 11 .
RPOA Type 2 is used for a condition of abnormal bone loss or destruction in a short period of time, including limited or total collapse of at least one subchondral surface that is not a feature of conventional advanced OA 12 .
A SIF may stabilize or heal with minor deformity or no deformity, or may progress to complete subchondral collapse. The latter is often referred to as SONK or SPONK in the knee joint 13 . For the purposes of this atlas, the term "SONK" will not be used as it is considered to be part of the spectrum of SIF and not a separate condition. SIF may be seen on radiography as a focal area of subchondral osteopenia and once articular surface deformities are present. MRI is more sensitive to detect early manifestations of SIF, once these are still potentially reversible and is able to define prognosis 14 .
Atrophic osteoarthritis is characterized by joint space narrowing (JSN) without relevant osteophyte formation and absence of erosions or other radiographic signs of inflammatory arthritis 15, 16 . In some cases, RPOA Type I is preceded by an atrophic OA appearance; therefore subjects exhibiting radiographic atrophic OA at the screening visit are commonly excluded from entering any study.
Severe malalignment may be a marker of more rapid OA progression and thus, may be an additional diagnosis of exclusion at eligibility. Cut-off values of severe malalignment are not defined in the literature and may vary. Commonly used cut-offs are between 6 or 10 varus or valgus in the anterioreposterior direction 17 .
Large areas of bone marrow edema without fracture line as visualized on fluid-sensitive fat-suppressed MRI are usually painful conditions and will explain incident or worsening of pain in a number of subjects 18, 19 . These can be part of the OA disease process especially if they are observed in a subchondral location 20 . They may also be the result of more acute overloading leading to a stress reaction that manifests itself as a large area of bone marrow edema, but does not show a characteristic hypointense fracture line 21 . "Idiopathic transient bone marrow edema" will present in identical fashion 22, 23 .
Diagnoses of exclusion for eligibility are those that potentially increase the risk of RPOA Type I or II. These are pre-existing atrophic OA and RPOA, SIF and potentially severe malalignment of the knee. Additional diagnoses of exclusion for eligibility may be severe chondrocalcinosis, which may be observed in association with OA 24 . However, the threshold definition for "severe" may vary between studies and the literature is not unequivocal in regard of rates of progression 25 . Other arthropathies, e.g., rheumatoid arthritis, gout, systemic metabolic bone or joint diseases are reasons for excluding subjects from entering a trial and if detected while on-study, a reason to recommend discontinuation of treatment but may vary between studies. These also include primary or metastatic malignant tumors consistent with grades 2 and 3 of the Lodwick classification 26, 27 . In addition, fractures (stress, traumatic, pathologic) detected by either radiography or MRI are reason to exclude a subject from entering a trial regardless of cause of fracture. Fractures are defined by a visible fracture line.
Diagnoses relevant for safety after enrollment (i.e., joint safety findings) are RPOA Types I and II, SIFs, osteonecrosis and pathologic fractures plus incidental findings of the entities described above. Several of these diagnoses have non-specific findings on the radiograph or cannot be detected radiographically in early stages. Thus, in cases of inconclusive or suspicious radiography an additional MRI examination will commonly be acquired to rule out or confirm some of these diagnoses especially in early stages and thus, MRI findings will be presented in addition.
The image acquisition process being defined in this atlas is that potential participants will be screened by radiography for eligibility criteria, using a conservative approach to allow subjects being included into the study. Once included into a study, radiography will still be the first line imaging approach, but MRI scans of any or all joints may be requested if needed (i.e., "for cause", commonly requested due to equivocal radiographic findings or discrepancies between radiography and clinical symptoms).
The term "adverse event(s)" is used throughout this atlas in relationship to clinical trials as defined by the FDA: "Adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related." 28 No causality or level of whether this is a "serious" adverse event is being attributed in this atlas.
The radiographic imaging acquisition protocol that is being recommended for the knee in aNGF studies is the posterioreanterior view in a modified Lyon-Schuss technique 29e31 . This technique has been shown to provide the best precision for evaluating JSN in clinical trials 32, 33 . The MRI protocol should be a standard clinical protocol or an abbreviated protocol consisting of at least a sagittal and coronal proton density or T2weighted fat suppressed sequence and a coronal or sagittal T1weighted non-fat suppressed sequence. The use of 1.5 T or 3 T large bore MRI is recommended for assessment of joints in aNGF studies. 1.0 T or 1.5 T extremity scanners may be used alternatively but are only applicable to image the knee joint and not other joints commonly assessed in aNGF studies such as the hip or shoulder.
Results
The radiographic appearance of atrophic osteoarthritis, one of the diagnoses of exclusion at eligibility is depicted in Fig. 1 . Figure 2 exemplifies a case of RPOA Type 1 over the course of 18 months. The catastrophic events of two cases of RPOA Type II are illustrated in Fig. 3 . Several examples of the spectrum of SIFs with or without focal areas of necrosis are illustrated in Figs. 4e8. Characteristic MRI findings of osteonecrosis (or bone infarcts) are shown in Fig. 9 . Examples of large areas of subchondral bone marrow edema in the context of OA or due to mechanical overload (i.e., stress reaction) without a fracture are shown in Fig. 10 . Figure 11 represents an example of transitory migrating bone marrow edema syndrome, a self-limiting entity that may affect several joints over time. Other arthropathies may be potential diagnoses for exclusion at screening and include severe chondrocalcinosis ( Fig. 12 ), inflammatory arthritis, pigmented villonodular synovitis (PVNS), or fracture, which may also be safety endpoint on study ( Figs. 13 and 14 ). Primary or secondary malignant bone tumors are a diagnosis of exclusion while some tumorlike entities such as enchondroma, non-ossifying fibroma or ganglion cysts may not. Some of these entities are shown in Figs. 15  and 16 . Finally, severe malalignment may be considered a risk factor for more rapid progression and thus, may be an exclusionary diagnosis at eligibility. An example of severe varus and valgus malalignment is shown in Fig. 16 . This atlas is not illustrating all potential diagnoses that might be relevant for eligibility or safety but covers the large majority of these. . Transient migratory bone marrow edema syndrome. A. At initial presentation this patient complained about diffuse pain in the left knee. A large area of bone marrow edema without fracture was observed in the medial femur. B. While pain receded on the left, incident pain in the right knee was reported 7 months later. A large area of bone marrow edema was seen in the medial femoral condyle of the right knee. C. After complete resolution of symptoms, 12 months later incident pain was reported in the left hindfoot. Now bone marrow edema was seen in the calcaneus (arrows). D. After 30 months of initial complaints in the left knee, a diagnosis of bone marrow edema (BME) was established in the left talus. Such a course is rare but not unusual. Complete resolution of all symptoms was observed after 3 years. Fig. 12 . Chondrocalcinosis is common in patients with OA and is a finding commonly to be expected in a-NGF patients. In some aNGF programs under development, severe chondrocalcinosis may be a reason for exclusion at eligibility due to potentially increased risk for on-study adverse events. A. Anterioreposterior radiograph shows mild chondroclacinosis in the medial (black arrows) and lateral (white arrow) tibiofemoral joint. B. Another knee exhibits mild chondrocalcinosis in the lateral tibiofemoral joint only (arrows). C. Mild to moderate intraarticular calcifications representing chondrocalcinosis are seen in this example medially (white arrows) and laterally (black arrows). D. Example of severe chondrocalcinosis with marked calcifications in the lateral tibiofemoral joint space (white arrows). In addition there is a so-called Stieda-Pellegrini fragment at the medial femoral condyle reflecting remote trauma to the medial collateral ligament (black arrow). Fig. 13 . Other arthropathies may be reasons for exclusion at eligibility and during the course of a study. These may include inflammatory arthritis and fractures. A. Radiograph shows typical bone erosion at the medial tibial plateau (arrow) consistent with rheumatoid arthritis. Note incidental finding of an area of partially sclerotic bone reflecting a metaphyseal femoral bone infarct (white arrows). B. Soft tissue opacities consistent with typical gout tophi are seen in the periarticular region of this knee (large arrows). In addition minor bony erosions are detected (small white arrows). C. Separate patellar ossicle (arrows) represents bipartite patella, an anatomical variant not to be mistaken for a fracture. D. In contrast, a sclerotic band in the metaphysal tibia of this knee joint represents healing response at the fracture site (arrows). Other arthropathies. A. Anterioreposterior radiograph shows a markedly deformed knee joint with collapse of the medial tibial plateau. Note large subchondral cystic areas in the periarticular femur and tibia (arrows). B. Lateral radiograph confirms severe osteoarthritic changes with joint deformity. A definite diagnosis cannot be established based on radiograph alone, but joint deformity is consistent with RPOA Type II and thus, a diagnosis of exclusion. C. The additional coronal fat suppressed T2-weighted MRI shows a large mass of diffuse hypointensity reflecting susceptibility artifacts (asterisks). D. Corresponding sagittal T1-weighted MRI confirms hypointense mass-like lesion within the joint cavity (asterisk). This is the typical appearance of PVNS characterized by hemosiderin deposits. Fig. 15 . Tumor-like and cystic lesions may or may not be a diagnosis of exclusion depending on size, bengin or malignant appearance and particularly based on potential risk of fracture. A. Radiograph shows typical multilobulated and expansive appearance of fibrous dysplasia, a benign condition. As lesion occupies a large proportion of tibia this represents a finding of exlcusion. B. Metaphyseal cystic lesion with sclerotic rim (arrows). No definite diagnosis can be established based on X-ray alone but lesion appears to be definitely benign. However, as lesion in its entirety occupies more than 1/3 of bone in both views, the a.p. and lateral, this would be considered a lesion of exclusion due to increased racture risk. C. Typical finding of a non-ossifying fibroma of the metaphyseal femur. Lesion is well-demarcated and shows a sclerotic rim (arrows). The lateral radiograph showed that lesion only occupied the posterior quarter of the femur, and thus, this would not be a diagnosis of exclusion. D. Typical finding of a tibial metaphyseal enchondroma with multilobulated popcorn-like appearance (arrows). Benign incidental finding and no diagnosis for exclusion. Fig. 16 . A. Typical finding of a malignant bone tumor with spiculated cortex and partly lytic, partly sclerotic appearance. Finding represents an osteosarcoma, a definite diagnosis for exclusion. B. Systemic disease may be a reason for exclusion. This example shows severe joint destruction due to repetitive intraarticular hemorrhage in a hemophilic patient. C. Severe malalignment is not uniformly defined but may be a diagnosis for patient exclusion at eligibility. Example shows 10 varus malalignement as measured using the anatomical axis. D. Severe valgus malalignment of 11 is shown in this example, which may be reason for ineligibility.
